Elixir Medical bioresorbable stent gets CE mark; Alnylam announces Phase I success for hemophilia med;

> Elixir Medical has received a CE mark for its DESolve 100 novolimus-eluting bioresorbable coronary scaffold, named after its 100-micron strut profile and designed to degrade within a year. It will be available commercially in 2015. Story

> Alnylam ($ALNY) said ALN-AT3, an RNAi treatment for hemophilia and other bleeding disorders, succeeded in a Phase I trial. Release